At a Glance
- Harmony Biosciences Holdings (HRMY) shares experienced a significant surge of 12.7% in the recent trading session, closing at $29.6.
- This stock appreciation was driven by strong preliminary third-quarter 2025 results, with the Wakix franchise showing a 29% year-over-year revenue increase.
- The company has also revised its full-year 2025 revenue guidance upward, now expecting sales between $845 and $865 million.
- Analysts anticipate the company to report quarterly earnings per share of $0.83 and revenues of $220.95 million for the upcoming report.
- Harmony Biosciences currently holds a Zacks Rank #3 (Hold), indicating a neutral stance from analysts.
Harmony Biosciences Stock Surges on Strong Q3 Prelims
Harmony Biosciences Holdings, Inc. (HRMY) saw its shares climb by 12.7% in the last trading session, concluding at $29.6. This notable increase was accompanied by robust trading volume, with significantly more shares exchanged than on a typical day. This performance contrasts with the stock’s previous four-week period, during which it declined by 1.8%.
The stock’s upward momentum follows the company’s announcement of encouraging preliminary results for the third quarter of 2025. Revenues generated by the Wakix (pitolisant) franchise reached approximately $239 million in Q3 2025, marking a substantial 29% increase compared to the same period in the prior year. In addition to these strong quarterly figures, Harmony Biosciences has also enhanced its revenue outlook for the entirety of 2025. The company now projects revenues to fall within the $845-$865 million range, an upward revision from its earlier forecast of $820-$860 million. Harmony Biosciences is scheduled to release its official third-quarter 2025 earnings report on November 4th.
Analyst Expectations and Earnings Outlook
Looking ahead to the upcoming earnings report, analysts are projecting that Harmony Biosciences will post quarterly earnings per share of $0.83. This figure represents a modest year-over-year increase of 5.1%. Revenue expectations for the quarter stand at $220.95 million, indicating an anticipated growth of 18.8% from the corresponding quarter in the previous year.
💡 While strong revenue and earnings growth figures are critical indicators when assessing a stock’s potential, empirical studies highlight a significant correlation between revisions in earnings estimates and short-term stock price movements.
📌 For Harmony Biosciences, the consensus Earnings Per Share (EPS) estimate for the upcoming quarter has remained consistent over the past 30 days. Typically, a stock’s price may not sustain an upward trend in the absence of any discernible trend in earnings estimate revisions. Therefore, it is advisable to monitor HRMY closely to determine if this recent price surge indicates sustained strength in the near future.
Industry Context and Peer Performance
Harmony Biosciences currently holds a Zacks Rank #3 (Hold). This ranking suggests a neutral outlook from Zacks Investment Research.
The company operates within the Zacks Medical – Biomedical and Genetics industry. Within this sector, another company, Oculis Holding AG (OCS), concluded its recent trading session with a modest gain of 0.7%, closing at $21.35. OCS has demonstrated positive performance over the past month, delivering a return of 19.6%.
For Oculis Holding AG, the consensus EPS estimate for its forthcoming report has remained unchanged over the last month at -$0.5. When compared to the company’s EPS from the same period a year ago, this represents a change of +9.1%. Oculis Holding AG also currently carries a Zacks Rank of #3 (Hold).
Expert Summary
Harmony Biosciences (HRMY) experienced a significant stock price increase following positive preliminary Q3 2025 results and an upward revision of its full-year revenue guidance. Analysts maintain expectations for continued earnings and revenue growth in the upcoming report. The company’s performance and analyst ratings place it within the context of the Medical – Biomedical and Genetics industry.